The developments in ensemble deep learning (EDL) models used to characterize and estimate AD.
A decade after its first FDA approval, Takeda expands label of HyQvia to include rare autoimmune disorder
The FDA on Monday extended the label for Takeda’s HyQvia (immune globulin infusion 10% [human] with recombinant human hyaluronidase) as a maintenance therapy to prevent
January 17, 2024